Sintx Technologies, Inc.
No SEC Form 4 filings for $SINT in the last 30 days.
See all $SINT insider activity →Sintx Technologies reported a Q2 2026 transition toward a commercial biomaterials and medical technology platform. Revenue rose 199% on OEM industrial demand and pricing, with gross margin near 62%. Management cited a $3.2M backlog to convert into revenue, SiNAPTIC wedge first clinical use in March 2026, and Q3/Q4 revenue guidance of $0.9M-$1.1M and $1.0M-$1.3M, while noting going-concern financing needs.
Sintx Technologies, Inc. (SINT) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0001269026 0001269026 2026-08-11 2026-08-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
Sintx Technologies, Inc. (SINT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.2 3 ex4-2.htm EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER T
Over the past 7 days, alphai's AI scored 2 news stories mentioning SINT (Sintx Technologies, Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent SINT coverage spans financial news, earnings and corporate actions.
Guidance and backlog timing plus going-concern financing plans are likely to drive near-term risk premium and trading volatility.
This is a company-specific disclosure tied to its quarterly reporting and revenue outlook, but the scraped text does not include the actual financial figures or guidance numbers.
The 8-K discloses a warrant issuance (MedTech Ceramics, LP as holder) that can create future dilution/overhang depending on exercise terms and likelihood.
New board members with aerospace/semiconductor/AI investing backgrounds could support fundraising, partnerships, and credibility with institutional investors.
Street sentiment is turning more constructive via a fresh reiterated Buy and a high target, but the article also highlights weak fundamentals from the latest earnings.
alphai scores every news story that mentions SINT with an AI model for sentiment and relevance, and aggregates insider trades from Sintx Technologies, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Sintx Technologies reported a Q2 2026 transition toward a commercial biomaterials and medical technology platform. Revenue rose 199% on OEM industrial demand and pricing, with gross margin near 62%. Management cited a $3.2M backlog to convert into revenue, SiNAPTIC wedge first clinical use in March 2026, and Q3/Q4 revenue guidance of $0.9M-$1.1M and $1.0M-$1.3M, while noting going-concern financing needs.
6 min readSintx Technologies, Inc. (SINT) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0001269026 0001269026 2026-08-11 2026-08-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
2 min readSintx Technologies, Inc. (SINT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.2 3 ex4-2.htm EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER T
3 min readSyntiant Corp. said it appointed Adam Spice, CFO of Rocket Lab (Nasdaq: RKLB), and David Lam, CIO of Lam Frontier Technologies, to its board. The company cited Spice’s 25+ years of aerospace/technology finance leadership and Lam’s 25+ years investing in semiconductors and AI. Syntiant said the appointments support its growth and investor engagement.
2 min readMaxim Group reiterated a “Buy” rating on Sintx Technologies (NASDAQ:SINT) and set a $6.00 price target, implying 169.66% upside from the prior close, according to Benzinga. Other firms cited include Ascendiant (cut target to $12, Buy), Weiss (sell), and HC Wainwright (Buy, $10). SINT last traded at $2.23. The company reported Q EPS of ($0.70) vs ($0.66) consensus and revenue of $0.38M vs $0.30M.
4 min readClinical evaluation of the product by design surgeons completed, driving early commercial momentum ...
4 min readDoes SINTX TECHNOLOGIES, INC. (SINT) have what it takes to be a top stock pick for momentum investors? Let's find out.
3 min readNew U.S. Patent reinforces competitive advantage and enables broader licensing and product opportunities across key markets
2 min readSALT LAKE CITY, Utah, Sept. 08, 2025 ( GLOBE NEWSWIRE ) -- SINTX Technologies, Inc. ( NASDAQ: SINT ) ( "SINTX" or the "Company" ) , an advanced ceramics innovator specializing in biomedical applications of silicon nitride ( Si₃N₄ ) , today announced the entry into definitive agreements for the ...
3 min readShares of SINTX Technologies are trading sharply higher Wednesday morning. The stock is gaining following the announcement of a landmark study. Get a Year of Fast, Actionable Trade Alerts for 60% Off This Labor Day
3 min read
